| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PNAS..112.6979L |
| P356 | DOI | 10.1073/PNAS.1423900112 |
| P932 | PMC publication ID | 4460473 |
| P698 | PubMed publication ID | 26038551 |
| P50 | author | David K. Chalmers | Q43296593 |
| Gilda Tachedjian | Q57006431 | ||
| Stephen J Headey | Q73161340 | ||
| Nicolas Sluis-Cremer | Q113121065 | ||
| P2093 | author name string | Adam Johnson | |
| Jamie S Simpson | |||
| Catherine F Latham | |||
| Kelly D Huber | |||
| Jennifer La | |||
| David Tyssen | |||
| Ricky N Tinetti | |||
| P2860 | cites work | Murine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptase | Q24647519 |
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design | Q27651402 | ||
| Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action | Q27659605 | ||
| Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening | Q27675974 | ||
| Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery | Q27679154 | ||
| Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? | Q27683344 | ||
| N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance | Q28471689 | ||
| Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action | Q28829256 | ||
| Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
| The determination of enzyme inhibitor constants | Q29618526 | ||
| A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity | Q33196450 | ||
| Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. | Q33786075 | ||
| Antiretroviral therapy in the clinic | Q33877347 | ||
| Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies | Q33945786 | ||
| A ‘Rule of Three’ for fragment-based lead discovery? | Q33973131 | ||
| Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence | Q34313002 | ||
| Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90. | Q34353935 | ||
| Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series | Q34643481 | ||
| Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action | Q35185934 | ||
| A decade of fragment-based drug design: strategic advances and lessons learned | Q36732253 | ||
| Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs | Q37003938 | ||
| NMR methods in fragment screening: theory and a comparison with other biophysical techniques | Q37588998 | ||
| Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance | Q38299698 | ||
| Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. | Q38339368 | ||
| 2014 Update of the drug resistance mutations in HIV-1 | Q39498339 | ||
| Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone | Q41120477 | ||
| HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. | Q41879018 | ||
| Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442 | Q42278294 | ||
| Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision | Q46892314 | ||
| Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. | Q47624236 | ||
| Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors. | Q50931641 | ||
| Ligand efficiency indices as guideposts for drug discovery. | Q55040766 | ||
| PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening | Q58854342 | ||
| Discovery of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Competing with the Nucleotide Substrate | Q60197493 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6979-6984 | |
| P577 | publication date | 2015-05-18 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening | |
| P478 | volume | 112 |
| Q38587368 | Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q36262959 | Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design |
| Q47563456 | Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent |
Search more.